Renovaro BioSciences announces strategic restructuring, leadership transition

Renovaro announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company’s AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD. RenoVision: 2.0 Bold Strategic Vision to Be Expertly Implemented by New Executive Leadership Team Led by David Weinstein, CEO, Renowned Senior Wall Street Executive with 39 years in Banking & Analyst Roles, Recognized for Developing Dynamic Growth Strategies for a Broad Range of Private and Public Companies with a Focus on Maximizing the Value of Innovative Life Science Platforms. Accomplished, Committed, & Fully Engaged Board-of-Directors Actively Contributing to Next Stage of Growth with Renewed Sense of Urgency. James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International. Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus. Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics. Revitalized Commitment to “Ambitious Innovation” Includes: Strategic Asset Review & Pipeline Prioritization. Commitment to Develop RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships. Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement. Financial Initiatives to Ensure Company’s Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline. Synchronizing All Aspects of Renovaro’s Business Units to Yield Maximum Benefits to Patients and Shareholders.